Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
CAPR has been in the news recently: Capricor Therapeutics reported positive four-year safety and efficacy results from its HOPE-2 study of Deramiocel, a treatment for Duchenne Muscular Dystrophy. This announcement comes amid a broader market decline, with U.S. stock futures, including Dow futures, down about 0.2%.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
